Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 608 matching trials from the live ClinicalTrials.gov search.
Conditions
Haemophilus Influenzae Type B Infection
Interventions
Vaxelis, PedvaxHIB
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
6 Weeks to 12 Weeks
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
5
States / cities
Anchorage, Alaska • Chinle, Arizona • Fort Defiance, Arizona + 2 more
Completed Phase 1 Interventional Accepts healthy volunteers

Invaplex 50 Vaccine Dose-Ranging

NCT00082069
Conditions
Diarrhea
Interventions
Shigella flexneri 2a Invaplex 50
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Silver Spring, Maryland
Conditions
Acinetobacter Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Cholera, Cholera Vaccine Toxicity
Interventions
PanChol
Biological
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Lyme Disease, Post-Treatment Lyme Disease, Chronic Lyme Disease, Tick-Borne Infections, Pregnancy Complications, Child Development
Interventions
Neurodevelopmental assessments and follow-up
Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Completed No phase listed Observational Accepts healthy volunteers Results available

Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHER™ System

NCT01733069
Conditions
Chlamydia Trachomatis, Neisseria Gonorrhoeae Infection
Interventions
APTIMA COMBO 2 Assay (AC2 Assay)
Device
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
14 Years and older
Enrollment
1,912 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
7
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • Fall River, Massachusetts + 4 more
Conditions
Lung Diseases, Obstructive, Sarcoidosis, Wegener's Granulomatosis, Rhinoscleroma, Recurrent Respiratory Papillomatosis
Interventions
CryoSpray Ablation
Device
Lead sponsor
CSA Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Maternal Syphilis During Pregnancy - Baby Not Yet Delivered, Congenital Syphilis
Interventions
Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ)
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
San Jose, California • Stanford, California
Conditions
Typhoid Fever
Interventions
BB IND 6989
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Clostridium Difficile Immunisation, Diphtheria, Diphtheria Immunisation, Pertussis, Tetanus, Tetanus Immunisation
Interventions
Tetanus and Diphtheria Toxoids Adsorbed, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
399 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Shigella Vaccine and Challenge

NCT04242264
Conditions
Immunisation, Shigella Infection
Interventions
Placebo, Shigella sonnei strain 53G, WRSs2
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Decatur, Georgia • Cincinnati, Ohio
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine

NCT04094883
Conditions
Neisseria Gonorrhoeae Infection
Interventions
Meningococcal Group B Vaccine
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 25 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Not listed Phase 2 Interventional Accepts healthy volunteers

ACE393-103 Vaccination Challenge Study

NCT00859716
Conditions
Campylobacter Infection
Interventions
ACE393, Placebo vaccine
Biological
Lead sponsor
TD Vaccines A/S
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

NCT00346073
Conditions
Acellular Pertussis, Diphtheria, Tetanus
Interventions
Boostrix™, ADACEL®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 64 Years
Enrollment
2,337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
42
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 36 more
Conditions
Syphilis
Interventions
Doxycycline 200mg daily for 14 days
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Diarrhea
Interventions
CssBA, dmLT
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Silver Spring, Maryland
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine

NCT00347958
Conditions
Tetanus, Diphtheria, Pertussis
Interventions
Tetanus-diphtheria-acellular pertussis (Tdap) vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
15 Years to 69 Years
Enrollment
545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
4
States / cities
Jonesboro, Arkansas • Bossier City, Louisiana • University Heights, Ohio + 1 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Lay Health Advisors for Sexually Transmitted Disease Prevention

NCT00207506
Conditions
Syphilis, Gonorrhea, Chlamydia Infections, HIV Infections
Interventions
HoMBReS: A lay health advisor approach to STD prevention
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older · Male only
Enrollment
354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed No phase listed Observational Accepts healthy volunteers

Immunopathogenesis of Chlamydia

NCT00607659
Conditions
CHLAMYDIA INFECTIONS
Interventions
No intervention, only observational
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
11 Years to 21 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of Rifaximin in Preventing Campylobacteriosis

NCT02280044
Conditions
Dysentery, Diarrhea, Enteric Campylobacteriosis
Interventions
Rifaximin intervention, Placebo intervention
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

NCT02094586
Conditions
Cholera
Interventions
PXVX0200 Lot A, PXVX0200 Lot B, PXVX0200 Lot C, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 45 Years
Enrollment
3,146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
19
States / cities
Mobile, Alabama • Phoenix, Arizona • DeLand, Florida + 15 more
Conditions
Post-Treatment Lyme Disease
Interventions
taVNS
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Meningococcal Disease
Interventions
MenACWY-CRM, DTaP-IPV/Hib, HBV, PCV, MMR
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
55 Days to 89 Days
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
42
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more
Conditions
Antibiotic Resistant Infection
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Memphis, Tennessee • Houston, Texas